Silo Pharma, Inc. (SILO) Form 10-Q — May 13, 2026
Silo Pharma, Inc. reported a net loss of $1,647,117 for the three months ended March 31, 2026. The company's cash and cash equivalents decreased to $3,902,514 from $4,748,700, and its short-term investments remained relatively stable at $2,129,659. Research and development expenses for the quarter were $1,013,265, a significant increase from $593,962 in the same period last year.
Key figures
- Revenue
- 18026
- Total Debt
- 1336296
- Total Assets
- 7018132
- Cash Position
- 3902514
- Research And Development Expense
- 1013265
- Net Cash Used In Investing Activities
- 23563
- Net Cash Used In Operating Activities
- 822623
- Impairment Loss On Crypto Assets At Cost
- 29911
- Net Cash Provided By Financing Activities
- 0
- Unrealized Gain On Short Term Investments
- 2893
- Unrealized Loss On Short Term Tokenized Investment Funds
- 2060
Price after filing
1 day: +0.9%7 days: -4.6%30 days: +1550.0%
Close on the filing date to close N calendar days later (from $0.39). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.